9月22日，长川科技发布业绩预告，公司预计2025年前三季度实现归母净利润8.27亿元-8.77亿元，同比 增长131.39%至145.38%；其中，第三季度实现归母净利润4亿元-4.5亿元，同比增长180.67%至 215.75%。 对于业绩暴涨的原因，长川科技表示：本报告期内，半导体行业市场需求持续增长，公司客户需求旺 盛，产品订单充裕，销售收入同比大幅增长，使得利润同比大幅上升。 受此影响，9月23日，长川科技股价强势涨停，报收80.27元/股，创造历史新高，市值成功突破500亿元 大关。 长川科技主要为集成电路封装测试企业、晶圆制造企业、芯片设计企业等提供测试设备，目前长川科技 生产的集成电路测试机和分选机等产品已获得长电科技、华天科技、通富微电、士兰微、华润微电子、 日月光等多个一流集成电路厂商的使用和认可。 从去年财务数据来看，长川科技的业绩增长并非偶然，在2024年，长川科技实现营业收入36.42亿元， 同比大幅增长105.15%；取得归母净利润4.58亿元，同比暴涨915.14%。 分产品来看，测试机成为长川科技的核心增长引擎，在2024年，长川科技的测试机收入为20.63亿元， 同比大幅增长 ...

Core Viewpoint - The first batch of semi-annual reports from Shenzhen-listed companies shows significant growth, particularly for WoHua Pharmaceutical, which has boosted investor confidence and provided a positive signal for the pharmaceutical industry [1][2]. Company Performance - WoHua Pharmaceutical reported a revenue of 425 million yuan, a year-on-year increase of 7.64%, and a net profit of 44.68 million yuan, up 303.16% year-on-year [2][3]. - In Q2 2025, WoHua achieved a revenue of 208 million yuan, a 15.39% increase, and a net profit of 21.82 million yuan, soaring by 1442.6% [2]. - WoHua plans to distribute a cash dividend of 1.20 yuan per share to all shareholders [2]. Factors Driving Growth - The substantial increase in net profit for WoHua is attributed to strong performance in its core business and effective cost control [3]. - The company's unique medical insurance products have gained clinical recognition, with six new authoritative guidelines added in H1 2025, enhancing their market penetration [3]. - The growth reflects a synergy between pricing power and cost management, with unique products mitigating the impact of centralized procurement [3]. Industry Trends - The county-level medical market is expected to be a key growth area for pharmaceutical companies over the next three years, with early movers likely to benefit from structural advantages [4]. - Recent government policies aimed at supporting the pharmaceutical industry, including increased funding for new drug development and promoting the consistency of generic drug quality, create a favorable external environment [4]. Other Company Performances - Other companies in the first batch, such as Changchuan Technology, JuCan Optoelectronics, and Ruihu Mould, also reported revenue and profit growth, with Changchuan achieving a revenue of 2.167 billion yuan, up 41.80%, and a net profit of 427 million yuan, up 98.73% [6][7]. - Ruihu Mould reported a revenue of 1.662 billion yuan, a 48.30% increase, and a net profit of 227 million yuan, up 40.33% [7]. - JuCan Optoelectronics achieved a revenue of 1.594 billion yuan, a 19.51% increase, and a net profit of 117 million yuan, up 3.43% [8]. Market Overview - As of July 15, 2025, 775 Shenzhen companies had disclosed their semi-annual performance, with 453 companies (approximately 58.45%) expecting a year-on-year increase in net profit [9]. - Among the top 100 Shenzhen companies by market capitalization, only one did not report profit growth, highlighting the resilience of leading firms in a complex global economic environment [9].

Core Viewpoint - The first batch of semi-annual reports from five companies in the Shenzhen market shows positive revenue and net profit growth for four companies, with only *ST Lingda reporting a loss [1][4]. Group 1: Company Performance - Wohua Pharmaceutical achieved a revenue of 425 million yuan, a year-on-year increase of 7.64%, and a net profit of 44.68 million yuan, up 303.16% [1]. - Changchuan Technology reported a revenue of 2.167 billion yuan, a year-on-year increase of 41.80%, and a net profit of 427 million yuan, up 98.73% [2]. - Ruihu Mould achieved a revenue of 1.662 billion yuan, a year-on-year increase of 48.30%, and a net profit of 227 million yuan, up 40.33% [2][3]. - Jucan Optoelectronics reported record highs in revenue and net profit, with figures of 1.594 billion yuan and 117 million yuan, representing year-on-year increases of 19.51% and 3.43% respectively [3]. Group 2: Strategic Focus and Future Outlook - Wohua Pharmaceutical emphasized a strategy of cost reduction and efficiency improvement, focusing on intelligent equipment and lean production [1]. - Changchuan Technology highlighted its strong R&D investment of 577 million yuan, accounting for 26.65% of its revenue, and its extensive patent portfolio of over 1,150 [2]. - Ruihu Mould noted a strong order backlog in its automotive manufacturing equipment business, with expectations for revenue growth driven by new product launches [3]. - Jucan Optoelectronics plans to enhance operational efficiency and expand its product range with new high-end products in the second half of the year [3]. Group 3: Financial Challenges - *ST Lingda reported a revenue of 59.93 million yuan, a year-on-year increase of 72.39%, but a net loss of 105 million yuan, although the loss has narrowed compared to the previous year [4].

"宁波膜智信息科技有限公司"为势银（TrendBank）唯一工商注册实体及收款账户 势银研究： 势银产业研究服务 势银数据： 势银数据产品服务 势银咨询： 势银咨询顾问服务 重要会议： 4月29日，2025势银异质异构集成封装产业大会（浙江宁波） 点此报名 添加文末微信，加 先进封装 群 长川科技 董事、副总经理 钟锋浩 已 确认参 加 2025势银异质异构集成封装产业大会 ，并作为嘉宾进行主题为 《 Chiplet异构集成对测试技术 的挑战 》 的演讲。 钟锋浩， 长川科技董事、副总经理，高级工程师，专注集成电路测试装备研究开发近30 年，是集成电路测试装备领域一流资深技术专家，Chiplet测试标准编写组组长，全国集 成电路标准化技术委员会TC599专家成员。目前已申请集成电路测试技术相关专利79 项。 杭州长川科技股份有限公司 成立于2008年4月，是一家专注于集成电路封测装备研发、 生产和销售的高新技术企业，主要产品包括集成电路测试机、分选机、探针台、AOI设备 和自动化检测装备，客户包含了日月光、台积电、华天科技、长电科技、通富微电、矽 力杰等国内外一流集成电路企业。通过17年的技术积累和研发创新， ...